The Baveno Cooperation: an EASL Consortium

Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial) There is no evidence of a difference between carvedilol 12.5 mg daily and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. ....

🔗 Full paper: doi.org/10.1111/apt....

📝 Editorial by @reibergerthomas.bsky.social and Benedikt Simbrunner:
onlinelibrary.wiley.com/doi/epdf/10....

#LiverTwitter

Some evidence on role of Simvastatin and Carvedilol in patients after variceal🩸. Stage of cirrhosis and right combination may b the 🔑 for statins in PHTN
#LiverSky. @easlnews.bsky.social @bavenocoop.bsky.social @amcollegegastro.bsky.social @aasldnews.bsky.social

journals.lww.com/ajg/abstract...

Editor's Essential Reading ➡️

A review of the diagnosis and management of hemochrojmatosis, a genetic iron overload disease that is under diagnosed and treatable

Learn more: ow.ly/NIl350WuZoz

Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study Previous studies suggested that anticoagulation decreases the probability of developing portal hypertension (PHT)-related complications and improves survival in cirrhotic patients. Our study aimed to ...

CIRROXABAN Study is finally here!
🔬 First DB RCT evaluating rivaroxaban in cirrhosis
💡 Complication-free survival benefit in moderate liver dysfunction—Child‑Pugh B7 (HR 0.26 [95 % CI 0.07–0.90]).
⚠️ Mild bleeding ↑, but no increase in severe events.
📄 www.journal-of-hepatology.eu/article/S016...

Another piece of evidence about the role of anticoagulants in cirrhosis. Results of a multicenter effort. The cirroxaban study. @hospitalclinic.bsky.social @idibaps.bsky.social @jhepatology.bsky.social

kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...

New publication from the EASL AI Task Force This paper is more than a review: it is a consensus report by a group of 34 leading international experts in hepatology, data science, and artificial intelligen

What are the latest and concrete recommendations for the clinical application of AI in hepatology?🤖

Read now this position paper from the EASL AI Task Force from @jhepatology.bsky.social: easl.eu/news/new-pub...

#LiverSky

Fear of Biopsying...Liver Lesions

😀Nice review on evaluating L1-RADS 3 & 4 lesions:
www.gastrojournal.org/article/S001...

🤔How fearful should we be of tumor seeding from biopsies?

👍Apparently much less frequent than we thought..

Reassuring

#Gastrosky #Liversky

Jaume Bosch

No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx.

Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top.

RIP

#liversky

Illustration showing Functional Venous Insufficiency and Venous Hypertension. Along left side of image reads the following: Clinical Practice Nonsurgical Management of Chronic Venous Insufficiency Eri Fukaya, M.D., Ph.D., and Raghu Kolluri, M.D. Published December 18, 2024

Chronic venous insufficiency is mainly due to venous hypertension, the cause of which can be structural or functional. Treatment is aimed at decreasing venous hypertension through conservative, nonprocedural management.

Learn more in this December 2024 Clinical Practice article: nej.md/41Zd5Av

Adeu Jaume! Everything you taught us stay with us, and your beloved unit will carry on with the same spirit!Thank you for so many things🌹

REMEMBERING PROFESSOR JAUME BOSCH
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.

A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.

Rest in peace, Jaime

I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social

Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD

📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social

📖 July Editor's Essential Reading presents: Point-of-Care Ultrasound in #Gastroenterology and #Hepatology

🔗 ow.ly/poXQ50WfJcx

🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta

Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org

@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social

Image shows PDF.

Restrictive platelet transfusion strategies are recommended for various clinical populations to minimize adverse reactions, mitigate platelet shortages, reduce costs, and ensure patient-centric care.

#ISBTMilan

https://ja.ma/3FvGPfd

doi.org/10.1097/HEP....

@majathiele.bsky.social @reibergerthomas.bsky.social @aasldnews.bsky.social @bavenocoop.bsky.social

Monitoring resmetirom by LSM - asking for the moon?
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇

NEW ACG Clinical Guideline:

Malnutrition and Nutritional Recommendations in Liver Disease
Singal & Wong, et al.

📕 bit.ly/acg-guideline-liver-nutrition

📃 5 new EASL CPGs released today at
#EASLCongress!

✅ Make sure to attend the much awaited sessions listed below!

Time for Day 4 of #EASLConference

EASL/ESCMID symposium on #MDR infections in #cirrhosis starts at 08.30!

@easlnews.bsky.social
@escmid.bsky.social
@esgvh.bsky.social
G Ozkaya Sahin, @jasmohanbajaj.bsky.social
@oana-sandulescu.bsky.social, RB Demirtaş, J Fernandez

#Science #ID #Hepatology #AMR

Our group was very active at the EASL the home of Hepatology Congress in… | Annalisa Berzigotti Our group was very active at the EASL the home of Hepatology Congress in Amsterdam. Here our Manuel Prampolini presenting his and Eric F.’s oral poster on MeCP2! Congratulations! Jordi Gracia-Sancho,...

www.linkedin.com/posts/annali...

That’s a wrap on #EASLCongress2025! 💙 Thanks to all 7,742 attendees from 119 countries and all those who made this event possible! 🌍

See you in Barcelona on 27–30 May 2026!

Look back at the unforgettable moments easl.smugmug.com/EASL-Congres...
Best of slide decks: easlcampus.eu/Documents/be...

Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky

🆕CPG in press❕

EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease

Find it here👉https://bit.ly/3GM9EEB

#LiverSky
@easlnews.bsky.social

#EASL2025 #liversky

📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS!
🤝 See you at 10:30 Erlinger Room!
@bavenocoop.bsky.social #LiverSky

💊 DOACs in cirrhosis
🗣️ Cindy Pereira Portela (Lausanne) – #EASL2025
✅ Child A/B: ok (⚠️ no rivaroxaban in B)
🚫 Child C: not recommended
⭐ Apixaban might be the winner — but more data needed
🧩 Case-by-case decision
🤝 Multidisciplinary approach is essential